Newomics Closes $3.9M Series A Round

Aug 09, 2018

|

NEW YORK (GenomeWeb) – Mass spec technology firm Newomics has closed a $3.9 million Series A funding round.

The Berkeley, California-based company closed the round on Wednesday, said Daojing Wang, Newomics' founder and CEO, adding that it surpassed its initial target of $3.5 million. The round was led by the Berkeley Catalyst Fund and the Photon Fund.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Laureates Warn Against Hard Brexit

British Nobel laureates and Fields Medal winners warn that a 'hard' Brexit could harm science across the UK, the Guardian reports.

For All

Vox reports on inequities in genetic research and efforts to address them.

Lawrence Krauss to Retire Following Sexual Misconduct Allegations

The New York Times reports that Arizona State University's Lawrence Krauss is retiring following allegations of sexual misconduct.

This Week in PNAS

In PNAS this week: de novo NUS1 mutations linked to Parkinson's disease risk, candidate hepatocellular carcinoma drivers, and more.

Featured White Papers

A Mammalian System for Antibody/Protein Library Screening

xMAP Cookbook: A collection of methods and protocols for developing multiplex assays with xMAP Technology

Stroma Liquid Biopsy - Biomarkers of the Dysregulation of the Serum Proteome in Cancer

Cleanascite Lipid Removal & Clarification Reference Applications

Nov

15

Featured Webinar

Next-Generation Platforms for Strain Optimization: Reducing the Cost and Time for Commercializing Novel Biological Molecules

This webinar will discuss how Amyris, a biotechnology company that develops renewable products for a broad range of applications and industries, uses large-scale microbial engineering to support its manufacturing processes.

Dec

03

Featured Webinar

Application of a Novel ISH Approach to Elucidate Splice Variants in Schizophrenia

This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.

Main menu